Pliant Therapeutics, Inc.
PLRXHealthcareNASDAQBiotechnology · Last scanned Jul 22, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Pliant Therapeutics, Inc. focuses on Biotechnology services and products. Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. With a market capitalization of $67.5M, it sits in micro-cap territory. The company's lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that is in Phase 1a/1b for the treatment of solid tumors.
Market Cap
$67.5M
Beta
1.22
P/E (TTM)
—
P/E (Fwd)
-1.35
EPS (TTM)
$-1.88
EPS (Fwd)
$-0.81
ROE
-53.6%
ROA
-25.8%
Cash
$170.9M
Total Debt
$28.8M
Free CF
-$66.0M
52W Change
-30.6%
Annual Financials
Cash vs Debt
Where PLRX stands vs its 150-day and 200-day moving averages
As of the July 15, 2026 close, PLRX finished 11.38% below its 150-day moving average ($1.23) and 17.42% below its 200-day moving average ($1.32). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is PLRX overbought or oversold?
At the July 15, 2026 close, PLRX's RSI(14) was 38.7, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $170.9M in cash comfortably exceeding the $28.8M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$66.0M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -53.6%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $9.7M (2022) to $0 (2025), a 100% decline worth watching.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Pliant Therapeutics, Inc. and its sector.